Pyloric stenosis usually presents with non-bilious projectile vomiting during the third to fourth week of life. It is now clear that pyloric stenosis is caused by the selective inadequate development ...

Molybdenum cofactor deficiency (MoCD) is a group of ultrarare autosomal-recessive disorders in which impaired biosynthesis of the molybdenum cofactor (MoCo) abolishes the activity of all Mo-dependent ...

Nulibry replaces missing cyclic pyranopterin monophosphate, which is needed to reduce levels of neurotoxic sulfites. The Food and Drug Administration (FDA) has approved Nulibry ™ (fosdenopterin) for ...

MoCD Type A is a rare, inborn error of metabolism caused by mutations in the MOCS1 gene that results in toxic sulfite accumulation in the brain. Nulibry ...

It affects around one in 200,000 to 500,000 newborns and is caused by genetic mutations that lead to the loss of the molybdenum cofactor (Moco). Ultimately, several enzymes in the newborn's metabolism ...

Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The "Sickle Cell Disease - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. A recent epidemiological forecast ...

LAUSANNE, Switzerland--Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc. (ALXN), today announced that the U.S. Food and Drug Administration (FDA) has granted a ...

Today, the U.S. Food and Drug Administration approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality ...

Manuscript in the Journal of Inherited Metabolic Disease indicates increased survival in patients treated with fosdenopterin SOLANA BEACH, Calif., April 2, 2025 /PRNewswire/ -- Sentynl Therapeutics, ...

Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...